04.04.2017 • TopicsDr. Gerd BergmannNordmannNRC

‘It’s Going to Be a Marathon, Not a Quick Race’

Peter Wilkes, managing director, Biesterfeld Spezialchemie
Peter Wilkes, managing director, Biesterfeld Spezialchemie

“As always, innovation, no matter how big or small, creates opportunities for some while carrying burden for others. In this respect, digital transformation in chemical distribution seems to be one of these disruptors that will create a separating line between unlimited success and unavoidable failure, at least if you believe in the sometimes too overoptimistic round of experts.

We at Biesterfeld Spezialchemie also got infected by the hype and certainly believe that digitalization will be key to managing a successful future in chemical distribution. But our approach is more focused on the administrative part of doing business, ultimately adding efficiency to the procurement and sales process and making life easier for our partners.

We see that our true contribution in industries’ value chain is not to digitize traditional paperwork as such. Our primary role — being heavily involved in true specialty chemicals — is closely working with partners on product innovation, market development, optimization of customer formulations, providing superior technical service.

Largely, success is based on technical orientation, long-term relationship, trust and confidentiality when working with suppliers and customers. Those things are hard to replace by digital processes, meaning that transforming the chemical distribution model in the way we deploy it may naturally finds its limitations. Certainly, it’s going to be a marathon, not a quick race.”

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.